Join the club for FREE to access the whole archive and other member benefits.


Regenerative medicine company developing autologous cell therapies.

RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. 

We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.  

RepliCel is currently involved in three clinical development programs:  RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. 

In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018.   

Visit website:





Details last updated 29-May-2020

People at RepliCel

Lee Buckler

President, CEO and Director at RepliCel.

RepliCel News

RepliCel contracts Accerise to plan phase 2 cell therapy trials in Japan

Biospace - 19-May-2021

Successful trial results could bring us skin rejuvenation & tendon regeneration products


Interview with regenerative medicine RepliCel’s CEO

Digital Journal - 21-Sep-2017

Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal dam...

Topics mentioned on this page:
Regenerative Medicine, Hair loss